Introduction: Amyloid goiter is a rare disease characterized by amyloid deposits that cause sudden growth in the thyroid gland.
Case Presentation: Here we present a case of a 26-year-old woman with euthyroid amyloid goiter who presented with subacute granulomatous thyroiditis clinic. Amyloid goiter was detected as a result of core biopsy from the thyroid parenchyma of the patient with sudden thyroid enlargement. Surgery was not applied to the patient who had no pressure symptoms or signs. In systemic amyloidosis secondary to Familial Mediterranean fever, heart and kidney involvement, as well as the thyroid gland, were detected.
Conclusion: Amyloid accumulation should be considered in addition to anaplastic thyroid cancer and lymphoma in patients with sudden thyroid enlargement. It should not be overlooked that amyloid goiter may mimic subacute thyroiditis clinic. Systemic amyloidosis should be considered in patients with amyloid goiter, and an examination should be made to assess the presence of amyloid accumulations in other organs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1871530323666230907093422 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
miR-101-3p suppresses proliferation of orbital fibroblasts by targeting pentraxin-3 in thyroid eye disease.
PeerJ
November 2024
Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China.
Article Synopsis
- - The study investigates the role of miR-101-3p in the proliferation of orbital fibroblasts in thyroid eye disease (TED) and seeks to identify its targets, particularly focusing on pentraxin-3 (PTX3).
- - Research methods involved harvesting orbital adipose tissues from TED patients and control subjects, followed by various assays to assess fibroblast proliferation and apoptosis after manipulating miR-101-3p levels.
- - Results showed that miR-101-3p is downregulated in TED, and its overexpression inhibits fibroblast proliferation by targeting PTX3, enhancing understanding of TED's pathological mechanisms.
Amyloid Goiter: A Peruvian Case Series.
touchREV Endocrinol
October 2024
CaTaLiNA: Cancer de tiroides en Latinoamerica, Quito, Ecuador.
: Amyloid goiter (AG) is a rare cause of thyroid swelling, characterized by deposits of amyloid protein in the thyroid tissue. It can be associated with primary or secondary amyloidosis. Its prevalence in multinodular goiter cases is 0.
View Article and Find Full Text PDFAmyloid Goiter, Papillary Thyroid Carcinoma, and Diffuse Thyroid Lipomatosis: A Case Report of a Rare Association.
Cureus
October 2024
Division of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de Santo António, Unidade Local de Saúde de Santo António, Porto, PRT.
Article Synopsis
- Amyloid goiter is a rare thyroid condition linked to AL or AA amyloidosis and sometimes associated with lipomatosis or papillary thyroid carcinoma.
- A case of a 54-year-old male with chronic gout showed a thyroid ultrasound revealing a significant nodule, leading to a total thyroidectomy that discovered amyloid deposition and microcarcinomas.
- The report emphasizes the need for careful assessment in patients with thyroid enlargement, particularly those with inflammation, and highlights the necessity for more research on the connections between inflammation, amyloid, and thyroid cancer.
Thyroid Gland Diffuse Lipomatosis: A Case Study and Comprehensive Literature Review.
J Clin Med
October 2024
Department of Endocrine Surgery, Genesis Hospital, 54301 Thessaloniki, Greece.
Diffuse lipomatosis of the thyroid (DLT) is an uncommon condition where mature fat cells infiltrate the thyroid gland, disrupting its normal structure. Although rare, it typically manifests as neck enlargement or symptoms of compression, including breathing difficulties, trouble swallowing, and voice changes, which can complicate diagnosis. This report presents a case of a 61-year-old woman with DLT, who exhibited a multinodular goiter and progressive neck swelling, and examines 53 additional cases from the existing literature.
View Article and Find Full Text PDFPentraxin 3 mediates inflammation and adipogenesis in Graves' orbitopathy pathogenesis.
J Mol Endocrinol
November 2024
Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Pentraxin 3 (PTX3) is a prototypic humoral soluble pattern-recognition molecule known to function in immunity-related inflammation. Given the lack of information on the precise functions of PTX3 in the pathogenesis of Graves' orbitopathy (GO), this study investigated the role of PTX3 in the inflammation and adipogenesis mechanisms of GO. We first compared the PTX3 expression between orbital tissues from patients with GO and normal controls using real-time PCR, which estimated significantly higher PTX3 transcript levels in the GO tissues than in the normal tissues.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!